FeesSafety
Pluang+

Johnson & Johnson remains a strong dividend stock but trades at a premium valuation.

Company Fundamentals
22 Nov 2026, 20:38 WIB
Reuben Gregg Brewer
View Source
Bullish
Johnson & Johnson remains a strong dividend stock but trades at a premium valuation.

Johnson & Johnson continues to show resilience with a 64-year dividend increase streak and raised full-year revenue and earnings guidance for 2026. Despite its strong business fundamentals and leadership in pharmaceuticals and medical devices, the stock's high valuation ratios make it less attractive for value investors. It offers a modest 1.9% dividend yield, appealing mainly to conservative income-focused investors willing to pay a premium for quality and stability. Potential buyers might consider waiting for a market downturn to get a better entry price.

Johnson & Johnson trades at USD 270.47 on Pluang as of Nov 22, 2026, 21:01 WIB, up 1.25% for the day. The stock shows a 1.98% dividend yield and a market cap of $651.11 billion. Most Pluang users are buyers, with 96% of order activity favoring purchases at this time.

More News (JNJ)

Johnson & Johnson favored over Pfizer for steady growth and dividend in 2027 healthcare sector race

Johnson & Johnson favored over Pfizer for steady growth and dividend in 2027 healthcare sector race

Johnson & Johnson and Pfizer are key healthcare giants with differing strategies: J&J balances drug innovation and medical devices, while Pfizer focuses on oncology and obesity treatments. J&J reported stronger revenue growth and higher net income, w...

Market News
Neutral
1 hour ago
Johnson & Johnson remains a strong dividend stock but is pricey for value investors now.

Johnson & Johnson remains a strong dividend stock but is pricey for value investors now.

Johnson & Johnson continues to lead in pharmaceuticals and medical devices, boasting a 64-year streak of dividend increases. The company recently raised its full-year revenue and earnings guidance, reflecting solid business performance. However, its ...

Company Fundamentals
Bullish
5 hours ago
Johnson & Johnson favored over Pfizer for steady growth and dividend in 2027 healthcare sector race

Johnson & Johnson favored over Pfizer for steady growth and dividend in 2027 healthcare sector race

Johnson & Johnson and Pfizer, two healthcare giants, are taking different growth paths heading into 2027. Johnson & Johnson maintains a balanced business with strong pharmaceutical and medical device segments, showing steady revenue growth and a soli...

Market News
Neutral
6 hours ago
Dow drops nearly 950 points into correction as tech sell-off spreads and Fed rate hike looms

Dow drops nearly 950 points into correction as tech sell-off spreads and Fed rate hike looms

The Dow Jones Industrial Average fell nearly 950 points on Friday, entering correction territory by closing over 10% below its record high. The sell-off was driven by continued weakness in technology stocks, including a 14% drop in Nvidia after SEC a...

Bearish
9 hours ago
Dividend Aristocrats in Roth IRAs offer tax-free dividends and no required minimum distributions.

Dividend Aristocrats in Roth IRAs offer tax-free dividends and no required minimum distributions.

Dividend Aristocrats are S&P 500 companies with 25+ years of dividend increases, like Coca-Cola, Procter & Gamble, and Johnson & Johnson. Holding them in a Roth IRA shelters dividends from taxes, unlike taxable accounts where dividends face 15% or hi...

Bullish
1 day ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App